Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Breast Cancer Clinical Trial

Official title:

Clinical Study of Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04138719
• Other study ID #: CSPC-KAL-BC-11
• Status: Recruiting
• Phase: Phase 2
• Start date: November 20, 2019
• Est. completion date: June 20, 2021

Study information

• Verified date: November 2019
• Source: Hebei Medical University Fourth Hospital
• Contact: Cuizhi Geng, M.D.
• Phone: 0311-6669 6310
• Email: gengcuizhi[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, open, randomized, comparison study. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have <1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2.

Neoadjuvant therapy is often used to reduce the size of tumors, especially in locally advanced tumors. The purpose of this therapy is to make part of patients operable and to facilitate breast-conserving surgery.

The purpose of this study is to assess the efficacy and safety of the following two proposals: nab-paclitaxel plus carboplatin versus nab-paclitaxel plus epirubicin, in order to provide support for rational clinical application.

The total number of patients to be included in this study is 520 patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 520
• Est. completion date: June 20, 2021
• Est. primary completion date: October 20, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Females with age between 18 to 70 years old;

2. Histologically confirmed primary invasive breast cancer;

3. Histologically confirmed triple negative breast cancer;

4. Patients who planned to accept preoperative neoadjuvant therapy and had a mass larger than 2 cm.

5. Blood specimens and 5 sections of tumor tissue at baseline, blood specimens at surgery can be obtained.

6. Have at least one measurable lesion as per the RECIST criteria (version 1.1);

7. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to one;

8. LVEF=55%;

9. Bone marrow function:neutrophils (=1.5×10^9/L), platelets (=100×10^9/L), hemoglobin (=90 g/L);

10. Renal and hepatic function: Serum creatinine= 1.5×institutional upper limit of normal (ULN); AST and ALT = 2.5 × ULN; Total bilirubin=1.5×ULN, or patients with Gilbert's syndrome = 2.5 × ULN;

11. Patients had good compliance with the planned treatment, understood the research process and written informed consent.

Exclusion Criteria:

1. Previous treatment with any cytotoxic chemotherapy, endocrine therapy, biotherapy or radiotherapy;

2. Patients with heart disease above grade II (including grade II) identified by New York Heart Association (NYHA) scores;

3. Patients with severe systemic infection or other serious diseases;

4. Patients allergic to or intolerant of chemotherapeutic drugs or their adjuvants;

5. Patients with other malignant tumors in the past five years, except for cured cervical carcinoma in situ and non-melanoma skin cancer;

6. Pregnancy or lactation, as well as reproductive age patients who refused to take appropriate contraceptive measures in the trial;

7. Participation in any trial drug treatment or another interventional clinical trial 30 days before first dose was given;

8. The researchers considered the patients who were not suitable for enrollment.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Nab-paclitaxel
• Triple Negative Breast Neoplasms
• Triple-negative Breast Cancer

Intervention

Drug:
• Nab-paclitaxel + Carboplatin
nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles;
• Nab-paclitaxel + Epirubicin
nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and epirubicin given IV at 75 mg/m^2 on days 1 every 21 days x 6 cycles;

Locations

Country	Name	City	State
China	The Fourth Hospital of Hebei Medical University	Shijiazhuang	Hebei

Sponsors (3)

Lead Sponsor	Collaborator
Hebei Medical University Fourth Hospital	CSPC Ouyi Pharmaceutical Co., Ltd., The fifth medical center of PLA general hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	pCR (pathological complete response)	No residual infiltrating cancer cells were found in surgical specimens of breast and axillary lymph nodes; residual cancer cells in situ in surgical specimens can also be considered to achieve pCR	3 years
Secondary	Objective response rate (ORR)		3 years
Secondary	Disease free survival(DFS)		3 years
Secondary	Adverse events (AE)		3 years